ArticleJTCVS open2025
Thoracic endovascular aortic repair for advanced esophageal cancer invading the aorta: A prognosis analysis among 124 patients.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Advanced esophageal cancer invading the aorta is considered an unresectable disease with a poor prognosis. We evaluated the clinical impact of elective thoracic endovascular aortic repair implantation on the prognosis of such patients. Methods: We retrospectively evaluated patients with advanced esophageal cancer and aortic invasion who underwent thoracic endovascular aortic repair to assess its prognostic impact under multimodal treatment. Results: Overall, 124 patients were enrolled. Among these, 16 patients underwent salvage thoracic endovascular aortic repair in response to bleeding from an aorto-esophageal fistula, 46 patients received elective thoracic endovascular aortic repair with esophagectomy after diagnosing aortic invasion by a tumor, and 62 patients underwent elective thoracic endovascular aortic repair without esophagectomy after diagnosing aortic invasion by a tumor. The median overall survival time was 3.57, 6.90, and 16.90 months for patients who underwent salvage thoracic endovascular aortic repair, elective thoracic endovascular aortic repair without esophagectomy, and elective thoracic endovascular aortic repair with esophagectomy, respectively ( Conclusions: Compared with salvage thoracic endovascular aortic repair, elective thoracic endovascular aortic repair implanted after diagnosis for esophageal cancer with aortic invasion is associated with improved overall survival. It provides the opportunity for esophagectomy, further prolonging survival compared with those without esophagectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.